All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.
Research output: Book/Report › Commissioned report
Standard Standard
All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma. / Hughes, D.; Hughes, D.A.; All Wales Strategy Group., [No Value].
2008 ed. Unknown, 2008.
2008 ed. Unknown, 2008.
Research output: Book/Report › Commissioned report
HarvardHarvard
Hughes, D, Hughes, DA & All Wales Strategy Group., NV 2008, All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma. 2008 edn, Unknown.
APA
Hughes, D., Hughes, D. A., & All Wales Strategy Group., N. V. (2008). All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma. (2008 ed.) Unknown.
CBE
Hughes D, Hughes DA, All Wales Strategy Group. NV 2008. All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma. 2008 ed. Unknown.
MLA
Hughes, D., D.A. Hughes and [No Value] All Wales Strategy Group. All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma. 2008 udg. Unknown. 2008.
VancouverVancouver
Hughes D, Hughes DA, All Wales Strategy Group. NV. All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma. 2008 ed. Unknown, 2008.
Author
RIS
TY - BOOK
T1 - All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.
AU - Hughes, D.
AU - Hughes, D.A.
AU - All Wales Strategy Group., [No Value]
PY - 2008/1/1
Y1 - 2008/1/1
UR - http://www.wales.nhs.uk/sites3/Documents/371/FAR%20topotecan%20for%20company.pdf
M3 - Commissioned report
BT - All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.
PB - Unknown
ER -